Patent builds on previously granted U.S. patent as well as strengthens and diversifies the IP portfolio and further protects future revenues Southlake, Texas, Oct. 25, 2022 — Heart Test Laboratories, Inc. d/b/a…
CEO Andrew Simpson discusses how we’re one of the only companies leading the use of an AI-enabled EKG medical device to make it a far more valuable screening tool. https://twitter.com/i/status/1584532158261100545
Southlake, Texas, Oct. 20, 2022 — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as…
Chairman & CEO, Andrew Simpson, Describes AI-based Technology EKG Test and Next Steps for Commercialization https://youtu.be/0G8lDMfZnpA
Heart Test Laboratories' Chairman & CEO, Andrew Simpson, Describes AI-based Technology EKG Test and Next Steps for Commercialization https://youtu.be/0G8lDMfZnpA
Issuance of new reimbursement-related codes expected to accelerate the use and adoption of ECG-based cardiac dysfunction AI algorithms, including HeartSciences’ MyoVista October 19, 2022 — Heart Test Laboratories, Inc. d/b/a HeartSciences, a…
